NASDAQ:CCXI - ChemoCentryx, Inc.
$8.15
 $-0.01
-0.12%
11:45AM EDT
2019-07-22
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CCXI     avg for
industry  
  avg for
sector  
42 stocks weight:  25. 27   217. 37   399. 45  
42 stocks rank:  3. 00 K 1. 27 K 716. 99  
# analyst opinions:  7. 00   13. 21   13. 71  
mean recommendation:  1. 70   2. 10   2. 04  

quick ratio:  3. 36   5. 49   1. 88  
current ratio:  3. 43   5. 87   2. 36  

target price low:  14. 00   83. 44   114. 90  
target price avg:  19. 43   106. 20   137. 90  
target price high:  8. 59   132. 30   158. 97  
1-yr high:  14. 85   111. 86   142. 57  
last close:  8. 16   86. 79   125. 44  
50-day avg:  9. 82   86. 68   122. 63  
200-day avg:  10. 99   89. 22   121. 38  
1-yr low:  8. 11   69. 78   100. 51  
volume:  264. 99 K 2. 62 M 3. 43 M
50-day avg volume:  465. 17 K 3. 20 M 4. 16 M
200-day avg volume:  377. 89 K 2. 99 M 4. 75 M

1-day return:  -1. 45 % -1. 30 % -0. 99 %
this week return:  -4. 00 % 0. 45 % -0. 20 %
12-wk return:  -37. 80 % 0. 94 % 4. 84 %
52-wk return:  -34. 49 % -1. 30 % 10. 55 %

enterprise value (EV):  272. 76 M 45. 10 B 122. 38 B
market cap:  473. 67 M 38. 96 B 108. 40 B
EBITDA:  -42. 40 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -6. 43   5. 38   11. 93  
enterprise/revenue (EV/R):  6. 55   57. 92   10. 21  
total revenue:  41. 66 M 9. 91 B 39. 98 B
total debt:  21. 20 M 10. 90 B 17. 48 B
debt/equity:  26. 28   57. 18   120. 05  
net income (common):  -40. 50 M 2. 07 B 4. 05 B

shares outstanding:  50. 38 M 538. 09 M 1. 24 B
shares:  40. 47 M 548. 00 M 1. 22 B
shares short:  3. 21 M 10. 98 M 11. 87 M
shares short prior month:  1. 83 M 9. 32 M 12. 05 M
short ratio:  4. 58   5. 60   3. 34  
short % of float:  7. 26 % 6. 48 % 2. 64 %
total cash/share:  3. 83   10. 98   9. 19  
total cash:  222. 11 M 5. 93 B 6. 10 B
free cash flow:  -30. 14 M 2. 92 B 4. 55 B
operating cash flow:  -42. 80 M 3. 80 B 5. 78 B

book value:  1. 40   13. 35   27. 45  
price/book:  5. 84   4. 60   8. 78  
gross profits:  -19. 86 M 7. 44 B 36. 13 B
operating margins:  -103. 09 % -308. 40 % -28. 55 %
EBITDA margins:  -101. 79 % 13. 17 % 23. 38 %
profit margins:  -97. 22 % 10. 44 % 14. 18 %
gross margins:  -52. 07 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -0. 80   2. 10   4. 23  
forward EPS:  -1. 10   3. 45   7. 10  
P/E:  -10. 21   1. 90   32. 10  
forward P/E:  -7. 42   6. 46   15. 47  
PE/G:  0. 80   0. 70   -0. 54  
growth:  -12. 80 % 265. 63 % 79. 11 %
earnings high:  -0. 13   0. 89   1. 68  
earnings avg:  -0. 22   0. 70   1. 57  
earnings low:  -0. 27   0. 46   1. 46  
revenue high:  15. 00 M 2. 57 B 11. 07 B
revenue avg:  9. 83 M 2. 51 B 10. 91 B
revenue low:  8. 00 M 2. 45 B 10. 73 B
return on assets:  -12. 69 % -2. 34 % 5. 28 %
return on equity:  -76. 29 % -90. 08 % 133. 53 %
revenue growth:  -12. 80 % 265. 25 % 73. 68 %
revenue/share:  0. 82   12. 72   60. 04  

beta (1yr vs S&P500):  1. 08   1. 27   0. 91  
sharpe (1yr):  -0. 32   0. 16   0. 77  

held % insiders:  34. 73 % 6. 06 % 3. 29 %
held % institutions:  52. 96 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : CCXI
.    108.831 =       108.831 :: --> INITIAL WEIGHT <--
.    - 0.799 =       108.032 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.267 =       244.947 :: P/E factor
.    x 1.058 =       259.173 :: PE/G factor
.    x 1.506 =       390.353 :: beta factor
.    x 0.751 =       293.226 :: sharpe factor
.    x 2.584 =       757.802 :: current ratio factor
.    x 1.193 =       904.096 :: quick ratio factor
.    x 1.104 =       997.927 :: short ratio factor
.    x 1.113 =      1110.737 :: EV/R factor
.    x 1.071 =      1189.776 :: price-to-book factor
.    x 1.965 =      2338.349 :: debt-to-revenue factor
.    x 1.208 =      2825.103 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =       5991.46 :: sector+industry 1-year gains factor
.    x 1.009 =      6047.948 :: industry 12-weeks return factor
.    x 1.308 =      7910.042 :: industry 2-weeks return factor
.    x 0.924 =      7309.248 :: company one-year gains+dividend factor
.    x 2.073 =     15154.402 :: company 13 weeks' performance factor
.    x 0.982 =     14877.996 :: "drift" penalty 1 days ago
.    / 1.979 =      7518.682 :: overall "drift" factor
.    x 0.747 =      5617.408 :: largest single-day jump factor
.    x 0.111 =       622.773 :: low price factor
.    x 1.377 =       857.559 :: notable returns + performance factor
.    x 2.971 =      2548.035 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.     x 0.97 =      2471.893 :: forward EPS factor
.    x 0.989 =      2445.051 :: forward P/E factor
.    x 1.185 =      2896.683 :: industry recommendation factor
.    x 2.622 =      7595.948 :: company recommendation factor
.    x 1.003 =      7616.954 :: factor historical industry gain for week 29
.   x 10.833 =     82515.346 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        16.949 :: reduced for readability
.    + 8.319 =        25.267 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     25.267 :: FINAL WEIGHT for NASDAQ:CCXI


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org